An exploratory clinical study on the effects of SGLT2 inhibitors for type 2 diabetes (T2DM) patients with sleep apnea (SA)

An exploratory clinical study on the effects of SGLT2 inhibitors for type 2 diabetes (T2DM) patients with sleep apnea (SA) - An exploratory clinical study on the effects of SGLT2 inhibitors for type 2 diabetes (T2DM) patients with sleep apnea (SA)

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000031793

Enrollment

Registered

2018-03-19

Start date

2018-03-13

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

sleep apnea

Interventions

Sodium glucose cotransporter 2inhibitor

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Apnea Hypopnea Index over 15 patients with type 2 DM

Exclusion criteria

Exclusion criteria: Patients with moderate renal disease (eGFR<30 ml/min) patients with ketosis and diabetic coma patients with severe infection, perioperative period and severe trauma patients with poor control DM

Design outcomes

Primary

Measure	Time frame
Changes in apnea-hypopnea index (AHI), body weight, body composition, and HbA1c, as well as the levels of microalbuminuria and urine L-FABP	—

Countries

Japan

Contacts

Public ContactTakatoshi Kasai

Juntendo University Graduate School of Medicine Department of Cardiovascular Medicine, Cardiovascular Respiratory Sleep Medicine

tkasai@juntendo.ac.jp03-3813-3111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026